Evidence map›Paper›PMID 35798720›Full record

Trial reportBlood cancer journal2022

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Tomáš Stopka, Lubomír Minařík, Nina Dusilková, Michal Pešta, Vojtěch Kulvait, Martin Špaček, Zuzana Zemanová, Marta Kalousová, Anna Jonášová

Open access · goldAbstract readLetterRandomized Controlled Trial
In one paragraph

Trial report in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tomáš Stopka *Haematology Clinic, General Faculty Hospital, Prague, Czech Republic. tstopka@lf1.cuni.cz.ORCID http://orcid.org/0000-0001-7236-6894
Lubomír Minařík *Haematology Clinic, General Faculty Hospital, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-1019-2195
Nina DusilkováHaematology Clinic, General Faculty Hospital, Prague, Czech Republic.
Michal PeštaFaculty of Mathematics & Physics, Charles University, Prague, Czech Republic.
Vojtěch KulvaitBIOCEV, 1st Medical Faculty, Charles University, Vestec, Czech Republic.ORCID http://orcid.org/0000-0003-3279-3757
Martin ŠpačekHaematology Clinic, General Faculty Hospital, Prague, Czech Republic.
Zuzana ZemanováCytogenetics, 1st Medical Faculty, General Hospital and Charles University, Prague, Czech Republic.
Marta KalousováInstitute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital, Prague, Czech Republic.
Anna JonášováHaematology Clinic, General Faculty Hospital, Prague, Czech Republic. Anna.Jonasova@vfn.cz.ORCID http://orcid.org/0000-0003-0246-1524
Charles University · CZGeneral University Hospital in Prague · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationGA trial is registered under EudraCT#: 2013-001639-38.

Indexed as

AzacitidineMyelodysplastic SyndromesAntimetabolites, AntineoplasticGranulocyte Colony-Stimulating FactorHumansAntimetabolites, AntineoplasticAzacitidineGranulocyte Colony-Stimulating Factor

Identifiers

PMID35798720
PMCPMC9262924
OpenAlexW4284885220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.